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Aims Computed tomography coronary angiography (CTA) is an important non-invasive imaging modality increasingly used
for the diagnosis and prognosis of coronary artery disease (CAD). The purpose of the current study was to deter-
mine the influence of smoking status on the prognostic value of CTA in patients with suspected or known CAD.
Methods
and results
In 1207 patients (57% male, age 57+12 years) referred for CTA, the presence of significant CAD (≥50% stenosis)
was determined. During follow-up (FU) the following events were recorded: all cause mortality, and non-fatal infarc-
tion. The prognostic value of CTA in smokers and non-smokers was compared using an interaction term in the Cox
proportional hazard regression analysis. Significant CAD was observed in 327 patients (27%), and 273 patients (23%)
were smokers. During a median FU time of 2.2 years, an event occurred in 50 patients. After correction for baseline
characteristics including smoking in a multivariate model, significant CAD remained an independent predictor of
events. Furthermore, a significant interaction (P, 0.05) was observed between significant CAD and smoking. The
annualized event rate in smokers with significant CAD was 8.78% compared with 0.99% in smokers without signifi-
cant CAD (P, 0.001). In non-smokers with significant CAD the annualized event rate was 2.07% compared with
1.01% in non-smokers without significant CAD (P ¼ 0.058).
Conclusion The prognostic value of CTA was significantly influenced by smoking status. The event rates in patients with significant
CAD were approximately four-fold higher in smokers compared with non-smokers. These findings suggest that
smoking cessation needs to be aggressively pursued, especially in smokers with significant CAD.
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Introduction
The introduction of multi-slice computed tomography coronary
angiography (CTA) has changed the field of non-invasive imaging.
In contrast to functional imaging techniques assessing myocardial
perfusion and wall motion, CTA can provide direct non-invasive
anatomic assessment of the coronary arteries. Because of the
high negative predictive value for detection of significant coronary
artery disease (CAD) (defined as ≥50% stenosis),1 the technique
is increasingly used as a gatekeeper for further diagnostic testing. In
the last 3–4 years, several single and multicenter studies have
suggested that CTA may also provide important prognostic infor-
mation. These studies have shown that patients with significant
CAD detected on CTA are associated with worse outcome com-
pared with patients without significant CAD.2–7
Although the prognostic value of CTA and its incremental value
over baseline clinical variables have thus been previously described,
no reports have specifically focused on the prognostic value of
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CTA in smokers. This may be of interest, as smoking is an impor-
tant but also modifiable risk factor resulting in an approximately
two to four times increased risk of coronary heart disease com-
pared with non-smokers.8,9 Furthermore, smoking has recently
been shown to significantly increase the risk of events in asympto-
matic individuals with evidence of atherosclerosis according to the
coronary calcium score (CS), when compared with non-smokers
with a similar calcium burden.10 It is conceivable that smoking
has a similar effect on risk stratification with CTA. The purpose
of the current study was therefore to determine the influence of
smoking status on the prognostic value of CTA in patients with
suspected or known CAD.
Methods
The study population consisted of patients who were clinically referred
for CTA because of chest pain symptoms or a high risk profile for car-
diovascular disease. Patients were enrolled at the University Hospital in
Zurich, Switzerland, and at the Leiden University Medical Center, The
Netherlands. Results from this prospective registry have been pre-
viously published.5 Exclusion criteria were: cardiac arrhythmias, renal
insufficiency (defined as a glomerular filtration rate ,30 mL/min),
known hypersensitivity to iodine contrast media, and pregnancy. In
addition, patients with an uninterpretable CTA examination or coron-
ary artery bypass grafts were excluded. Clinical patient characteristics
were collected by the referring physician. Patients provided informed
consent and the study was approved by the local ethics committees
in both participating centres.
Computed tomography coronary
angiography acquisition and data analysis
Patients were scanned using a 64-row CT scanner (Aquilion64,
Toshiba Medical Systems, Otawara, Japan; and General Electrics Light-
Speed VCT, Milwaukee, WI, USA) or with a 320-row CT scanner
(Toshiba Multi-slice Aquilion ONE system, Toshiba Medical Systems,
Otawara, Japan). Before the examination, the patient’s heart rate and
blood pressure were monitored. In the absence of contraindications,
patients with a heart rate exceeding 65 beats per minute were admi-
nistered beta-blocking medication (50–100 mg metoprolol, oral or
5–10 mg metoprolol, intravenous). All scan parameters have been
previously published.11–13
Post-processing of the CTA examinations was performed on dedi-
cated workstations (Vitrea2 and VitreaFx, Vital Images, USA; and
Advantage GE Healthcare, USA). Computed tomography coronary
angiography examinations were read by two experienced readers at
both participating centres, blinded to follow-up (FU) results. Coronary
anatomy was assessed using a 17 segment model according to a modi-
fied American Heart Association classification.14 Normal CTA was
defined as completely normal anatomy or minimal wall irregularities
,30%, non-significant CAD was defined as the presence of luminal
narrowing with a maximal luminal diameter stenosis ,50%, and signifi-
cant CAD was defined as the presence of a lesion exceeding ≥50%
maximal luminal diameter stenosis.
Follow-up results
Patient FU data were gathered using clinical visits or standardized tele-
phone interviews. A composite endpoint was constructed using all
cause mortality, and non-fatal myocardial infarction. Non-fatal infarc-
tion was defined based on criteria of typical chest pain, elevated
cardiac enzyme levels, and typical changes on the electrocardiogram
(ECG).15 Patients with stable complaints undergoing an early elective
revascularization within 60 days after CTA were excluded from the
survival analysis.
Statistical analysis
Normally distributed continuous variables were expressed as mean
values (+standard deviation). Non-normally distributed continuous
variables were expressed as median values with a 25–75th percentile.
Categorical baseline data were expressed in numbers and percentages.
Differences between smokers and non-smokers were compared using
the Student t and x2 tests. Cox regression analysis was used to deter-
mine the prognostic value of significant (≥50% luminal narrowing)
CAD on CTA. First univariate analysis of baseline clinical variables,
and CTA was performed using a composite endpoint of all cause mor-
tality, and non-fatal infarction. For each variable a hazard ratio with a
95% confidence interval (95% CI) was calculated. A multivariate
model was created to assess the independent prognostic value of
CTA. To compare the prognostic value of CTA in smokers and non-
smokers a final multivariate model was constructed to test for inter-
action between smoking and CTA. Multivariate models were created
using stepwise backward elimination; first all baseline clinical variables
were included in the model, subsequently the least significant variable
was excluded one at a time until all variables in the model reached a
P-value of ,0.5. Annualized event rates were calculated based on
the number of events per 100 patient years FU. Survival curves
were estimated with the Kaplan–Meier method, and curves were com-
pared using the log-rank test. Statistical analyses were performed using
SPSS software (version 16.0, SPSS Inc., Chicago, IL, USA). A P-value of
,0.05 was considered statistically significant.
Results
The study population consisted of 1467 patients presenting at the
University Hospital Zurich (n ¼ 468), and at the Leiden University
Medical Center (n ¼ 999). In 44 (3%) patients the CTA examin-
ation was uninterpretable due to the presence of motion artefacts,
increased noise due to a high body mass index, and breathing. In
addition, 117 patients (8%) were lost to FU. Finally 99 patients
(7%) were excluded due to early revascularization. After exclusion,
a total of 1207 remained for analysis. The majority of patients were
symptomatic (67%), the remaining 33% of patients were referred
because of a high risk profile with or without an abnormal exercise
ECG. An overview of the baseline characteristics of the study
population is presented in Table 1.
Computed tomography coronary
angiography results
Significant CAD was observed on CTA in 327 patients (27%). In
the remaining 880 patients (73%) non-significant CAD was
observed in 425 patients (35%) and 455 patients (38%) were classi-
fied as normal. Figure 1 illustrates the prevalence of significant CAD
on CTA according to smoking status. In non-smokers (n ¼ 934),
significant stenosis was observed on CTA in 229 patients (25%),
compared with 98 (36%) of the 273 patients who smoked
(P, 0.001).
Follow-up results
The median FU time was 2.2 years (25–75th percentile: 1.3–3.2
years). During the FU period a myocardial infarction occurred in
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12 patients and all cause mortality was registered in 40 patients.
The composite endpoint of all cause mortality and myocardial
infarction occurred in 50 patients. This resulted in an event rate
of 1.8 per 100 patient years FU.
Survival analysis
The presence of significant CAD on CTA was a significant univari-
ate predictor of events (Table 2). After correction for baseline
clinical variables including smoking status, significant CAD
remained an independent predictor of events (Table 2). An
event rate of 4.01 events per 100 patient years FU was observed
in patients with significant CAD compared with 1.0 event per
100 patient years FU in patients without significant CAD.
To assess the prognostic value of significant CAD on CTA in
smokers and non-smokers, a second multivariate model was con-
structed to test for interaction (Table 3). The prognostic value of
CTA was significantly higher in smokers compared with the prog-
nostic value of CTA in non-smokers (interaction P ¼ 0.031). The
event rate in smokers with significant CAD was 8.78 events per
100 patient years FU compared with 0.99 events per 100 patient
years FU in smokers without significant CAD (P, 0.001). In
non-smokers with significant CAD the event rate was 2.07
events per 100 patient years FU compared with 1.01 events per
100 patient years FU in non-smokers without significant CAD
(P ¼ 0.058). The survival rate following CTA according to
smoking status is illustrated in Figure 2.
Discussion
The main finding of the current study comparing the prognostic
value of CTA in smokers and non-smokers is that the prognostic
value of significant CAD on CTA was significantly influenced by
smoking status. The event rate in patients with significant CAD
was approximately four-fold higher in smokers compared with
non-smokers. On the other hand, in patients without significant
CAD, the event rate was similar in smokers and non-smokers.
Although several studies have been published on the prognostic
value of CTA, to our knowledge this is the first report to describe
the effect of smoking on risk stratification with CTA. The effect of
smoking on the prognostic value of atherosclerosis as detected by
CS has been studied.10 Calcium score is generally used in asympto-
matic cohorts as a measure of atherosclerotic plaque burden, and
elevated CS are associated with an increased risk of events. In the
study by Shaw et al. in a large cohort of 10 377 asymptomatic individ-
uals, the value of CS for risk stratification has been compared
between smokers and non-smokers. The authors observed a signifi-
cant interaction between smoking and CS for the prediction of all
cause mortality. In each CS category the event rates in smokers
were higher than observed in non-smokers. In addition to this
imaging study in asymptomatic individuals, elevated event rates in
smokers when compared with non-smokers have also been
reported in symptomatic patients with established CAD. For
instance, several studies have shown that following revascularization,
smokers have a higher event rate than non-smokers.16–18 The
results of the current study are in line with these findings and
further strengthen the evidence that smokers with CAD have a
higher risk of events than non-smokers with similar levels of CAD.
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Table 1 Patient characteristics
Total (n5 1207) Non-smokers (n5 934) Smokers (n 5 273) P-value
Age (years) 56.8+ 11.9 57.4+ 12.2 54.8+ 10.9 0.002
Gender (male) 690 (57%) 514 (55%) 176 (64%) 0.006
Risk factors
Diabetes 299 (25%) 226 (24%) 73 (27%) 0.39
Hypertension 587 (49%) 455 (49%) 132 (49%) 0.92
Hypercholesterolaemia 461 (38%) 341 (37%) 120 (44%) 0.03
Family history of CAD 475 (39%) 342 (37%) 133 (49%) ,0.001
Obesity (BMI ≥ 30 kg/m2) 220 (18%) 176 (19%) 44 (16%) 0.26
History
Previous MI 96 (8%) 68 (7%) 28 (10%) 0.11
Previous PCI 116 (10%) 82 (9%) 34 (13%) 0.07
Known CAD 135 (11%) 96 (10%) 39 (14%) 0.07
BMI, body mass index; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention.
Figure 1 Relationship between computed tomography coron-
ary angiography findings and smoking.
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The observations in the current study may be explained in part
by the influence of smoking on the formation and progression of
atherosclerosis through its negative effects on vasomotor dys-
function, inflammation and lipid modification.19 Indeed multiple
reports have described the effects of smoking on the formation
of atherosclerosis both at autopsy,20 as well as in clinical
studies using coronary angiography,21,22 CS,23–25 and intima-
media thickness (IMT) measurements.26,27 Coronary angiography
studies have described that smoking is an important and indepen-
dent predictor of CAD, which is in line with the increased preva-
lence of significant CAD observed in the current study.21,22 Of
interest, the atherosclerotic process seems to occur earlier in
life in smokers.25,28 Earlier formation of CAD explains the
increased levels of CAD observed in smokers; however, this
may also be linked to increased progression of CAD. Smoking
has been associated with CAD progression both on coronary
angiography, IMT, and CTA. In a substudy of the CCAIT trial,
Waters et al.29 observed that smoking resulted in both plaque
progression and new plaque formation on serial quantitative
coronary angiography.
The rapid decrease in the risk of myocardial infarction observed
after smoking cessation suggests that in addition to the effects of
smoking on CAD formation and progression, smoking may also
be seen as a trigger for myocardial infarction.30 Smoking may
affect all three major factors defining high-risk patients that are vul-
nerable to myocardial infarction or sudden cardiac death: vulner-
able plaque, vulnerable blood, and vulnerable myocardium.31
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Table 3 Interaction between smoking and significant
coronary artery disease on computed tomography
coronary angiography
Exposure Patients Event HR (95% CI) P-value
Non-smoking
CTA, 50% 705 16 1.0 (reference)
CTA ≥ 50% 229 11 2.1 (0.9–4.5) 0.06
Smoking
CTA, 50% 175 4 1.0 (reference)
CTA ≥ 50% 98 19 8.9 (3.0–26.5) ,0.001
Interaction P ¼ 0.031 and P ¼ 0. 045 (adjusted for age, diabetes,
hypercholesterolaemia, obesity, and known CAD).
Figure 2 Survival according to computed tomography coron-
ary angiography in non-smokers (A) and smokers (B).
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Table 2 Univariate and multivariate predictors of events
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Age (years) 1.1 (1.0–1.1) ,0.001 1.1 (1.0–1.1) ,0.001
Gender (male) 1.1 (0.6–1.9) 0.68
Diabetes 1.6 (0.9–2.9) 0.11 1.8 (1.0–3.5) 0.07
Hypertension 1.2 (0.7–2.2) 0.46
Hypercholesterolaemia 1.1 (0.6–1.9) 0.67
Family history CAD 0.9 (0.5–1.6) 0.68
Obesity (BMI ≥ 30 kg/m2) 0.49 (0.2–1.2) 0.13 0.5 (0.2–1.3) 0.2
Known CAD 2.3 (1.2–4.3) 0.01 1.8 (0.9–3.5) 0.1
Current Smoking 2.9 (1.6–4.9) ,0.001 2.6 (1.4–4.7) ,0.05
Significant CAD 4.1 (2.3–7.2) ,0.001 2.4 (1.3–4.4) ,0.05
BMI, body mass index; CAD, coronary artery disease; HR, hazard ratio.
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Smoking has been associated with inflammatory processes, and
endothelial dysfunction which may increase plaque vulnerability
resulting in a higher risk of intracoronary thrombus formation. In
addition platelet function, antithrombotic/prothrombotic, and fibri-
nolytic factors may be altered by smoking resulting in an increased
thrombotic tendency which in turn may cause more frequent and
severe thrombus formation in response to plaque rupture.32–35
Finally, smoking results in activation of the sympathetic nervous
system thereby increasing heart rate and myocardial contractility
resulting in increased oxygen demand, while at the same time
decreasing myocardial oxygen supply due to vasoconstriction of
the coronary arteries.36 This mismatch in oxygen demand/supply
may increase the myocardial vulnerability to ischaemia thereby
unfavourably altering myocardial response to thrombotic
occlusions.
Clinical implications
Further studies are needed to confirm our finding that the relative
risk of events associated with significant CAD on CTA is signifi-
cantly higher in smokers compared with non-smokers. Neverthe-
less, our results do suggest that strategies aimed at preventing
future cardiovascular events should be intensified in patients with
significant CAD who smoke. This is further strengthened by the
fact that smoking is a modifiable risk factor, and that smoking
cessation has been shown to improve survival.37,38
Interestingly, when regarding patients without significant CAD,
the risk of events in smokers without significant CAD was
similar to the risk observed in their non-smoking counterparts.
On the basis of previous studies assessing effect of smoking on
CAD, it is expected that new formation and progression of (non-
significant) CAD should also be increased in patients without sig-
nificant CAD who smoke. The similar event rates observed in
the current study suggest that this effect may be more gradual.
Longer FU studies are necessary to determine the influence of
smoking status in patients without significant CAD.
Limitations
A limitation of the current study is that no exact data regarding
quantification of smoking were available. This would have been
of interest as several studies have suggested a dose–response
relationship between smoking and the severity of CAD. In addition,
the occurrence of passive smoking in the non-smoking subgroup
was not systematically recorded. Because passive smoking has
also been associated with an increased risk of events,39–42 a
similar interaction as observed between significant CAD and
active smoking may exist in passive smokers. Future studies are
necessary to further study these concepts.
A general limitation of CTA imaging is the high radiation dose
associated with traditional 64-slice CTA protocols, although the
radiation dose of CTA has decreased substantially with the
implementation of dose saving algorithms and novel acquisition
techniques.43–46 Importantly, low-dose CTA with prospective
ECG-triggering has recently been shown to reduce radiation
burden while maintaining image quality and a high diagnostic accu-
racy.47 Currently, the radiation burden with these novel acquisition
techniques is approaching ≤2 mSv.48
Conclusion
The prognostic value of CTA was significantly influenced by
smoking status. The event rates in patients with significant CAD
were approximately four-fold higher in smokers compared with
non-smokers. These results need to be confirmed in larger FU
studies, but suggest that smoking cessation needs to be aggressively
pursued, especially in smokers with significant CAD.
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